Results: The TNM stage III-IV CRC group had significantly higher blood levels of cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), CNR, and carcinoembryonic antigen (CEA), and shorter progression-free survival (PFS) than the TNM stage I-II CRC group (all, P < 0.05). The gene discussed is CEACAM5; the disease is colorectal carcinoma.